JPWO2020104531A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020104531A5 JPWO2020104531A5 JP2021527213A JP2021527213A JPWO2020104531A5 JP WO2020104531 A5 JPWO2020104531 A5 JP WO2020104531A5 JP 2021527213 A JP2021527213 A JP 2021527213A JP 2021527213 A JP2021527213 A JP 2021527213A JP WO2020104531 A5 JPWO2020104531 A5 JP WO2020104531A5
- Authority
- JP
- Japan
- Prior art keywords
- mva
- recombinant mva
- herv
- pharmaceutical composition
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 56
- 102000039446 nucleic acids Human genes 0.000 claims description 42
- 108020004707 nucleic acids Proteins 0.000 claims description 42
- 150000007523 nucleic acids Chemical class 0.000 claims description 42
- 239000000427 antigen Substances 0.000 claims description 25
- 102000036639 antigens Human genes 0.000 claims description 25
- 108091007433 antigens Proteins 0.000 claims description 25
- 230000001965 increasing effect Effects 0.000 claims description 22
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 230000004083 survival effect Effects 0.000 claims description 18
- 241000192019 Human endogenous retrovirus K Species 0.000 claims description 17
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 17
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 17
- 229940126546 immune checkpoint molecule Drugs 0.000 claims description 17
- 230000002601 intratumoral effect Effects 0.000 claims description 15
- 230000028709 inflammatory response Effects 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 206010046865 Vaccinia virus infection Diseases 0.000 claims description 13
- 239000005557 antagonist Substances 0.000 claims description 13
- 208000007089 vaccinia Diseases 0.000 claims description 13
- 239000000556 agonist Substances 0.000 claims description 12
- 102000002627 4-1BB Ligand Human genes 0.000 claims description 10
- 108010082808 4-1BB Ligand Proteins 0.000 claims description 10
- 108010029697 CD40 Ligand Proteins 0.000 claims description 10
- 102100032937 CD40 ligand Human genes 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 8
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 8
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 8
- 102100035703 Prostatic acid phosphatase Human genes 0.000 claims description 8
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 8
- 108010043671 prostatic acid phosphatase Proteins 0.000 claims description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 8
- 230000001177 retroviral effect Effects 0.000 claims description 7
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 102100035139 Folate receptor alpha Human genes 0.000 claims description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 4
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 claims description 4
- 102000017578 LAG3 Human genes 0.000 claims description 4
- 101150030213 Lag3 gene Proteins 0.000 claims description 4
- 108010008707 Mucin-1 Proteins 0.000 claims description 4
- 102000007298 Mucin-1 Human genes 0.000 claims description 4
- 102000036673 PRAME Human genes 0.000 claims description 4
- 108060006580 PRAME Proteins 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 108010002687 Survivin Proteins 0.000 claims description 4
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 8
- 230000002708 enhancing effect Effects 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 4
- 102000000763 Survivin Human genes 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 238000000034 method Methods 0.000 description 38
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 101710177291 Gag polyprotein Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 108010071967 protein K Proteins 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 102100034353 Integrase Human genes 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 108010078428 env Gene Products Proteins 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18207238.9 | 2018-11-20 | ||
| EP18207238 | 2018-11-20 | ||
| US201962807720P | 2019-02-19 | 2019-02-19 | |
| US62/807,720 | 2019-02-19 | ||
| PCT/EP2019/081942 WO2020104531A1 (en) | 2018-11-20 | 2019-11-20 | Therapy for treating cancer with an intratumoral and/or intravenous administration of a recombinant mva encoding 4-1bbl (cd137l) and/or cd40l |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022507744A JP2022507744A (ja) | 2022-01-18 |
| JPWO2020104531A5 true JPWO2020104531A5 (enExample) | 2022-10-26 |
| JP7625518B2 JP7625518B2 (ja) | 2025-02-03 |
Family
ID=68542659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021527213A Active JP7625518B2 (ja) | 2018-11-20 | 2019-11-20 | ４－１ｂｂｌ（ｃｄ１３７ｌ）及び／またはｃｄ４０ｌをコードする組み換えｍｖａの腫瘍内及び／または静脈内投与によって、がんを治療する療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12390515B2 (enExample) |
| EP (1) | EP3883599A1 (enExample) |
| JP (1) | JP7625518B2 (enExample) |
| KR (1) | KR20210094535A (enExample) |
| CN (1) | CN113056284A (enExample) |
| AU (1) | AU2019385665A1 (enExample) |
| BR (1) | BR112021009856A8 (enExample) |
| CA (1) | CA3119503A1 (enExample) |
| IL (1) | IL283187A (enExample) |
| MX (1) | MX2021005560A (enExample) |
| SG (1) | SG11202104918PA (enExample) |
| WO (1) | WO2020104531A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3073310A1 (en) * | 2017-08-24 | 2019-02-28 | Bavarian Nordic A/S | Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| IL293051A (en) | 2019-11-18 | 2022-07-01 | Janssen Biotech Inc | Vaccines based on mutant calr and jak2 and their uses |
| EP4061404A1 (en) | 2019-11-20 | 2022-09-28 | Bavarian Nordic A/S | Medical uses of 4-1bbl adjuvanted recombinant modified vaccinia virus ankara (mva) |
| IL293009B1 (en) * | 2019-11-20 | 2025-09-01 | Bavarian Nordic As | Recombinant mva viruses for intratumoral and/or intravenous administration for cancer treatment |
| WO2021207171A1 (en) * | 2020-04-06 | 2021-10-14 | St. Jude Children's Research Hospital, Inc. | B7-h3 chimeric antigen receptors |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| KR20240099343A (ko) * | 2021-10-26 | 2024-06-28 | 나비큐어 바이오파마슈티컬스 리미티드 | 암 및 감염병에 대한 병용 요법 |
| CA3240596A1 (en) | 2021-12-23 | 2023-06-29 | Cigdem ATAY LANGBEIN | Therapy for modulating immune response with recombinant mva encoding il-12 |
| WO2023118508A1 (en) * | 2021-12-23 | 2023-06-29 | Bavarian Nordic A/S | Recombinant mva viruses for intraperitoneal administration for treating cancer |
| CN117004579B (zh) * | 2023-06-29 | 2024-11-15 | 苏州恩立维生物科技有限公司 | 重组溶瘤牛痘病毒及其应用 |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| EP0247091B1 (en) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0436597B1 (en) | 1988-09-02 | 1997-04-02 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| EP1471142B1 (en) | 1991-04-10 | 2008-11-19 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| PT735893E (pt) | 1993-09-14 | 2009-03-06 | Pharmexa Inc | Péptidos que se ligam aos alelos pan dr para aumentar a resposta imunitária |
| AUPO390396A0 (en) | 1996-11-29 | 1996-12-19 | Csl Limited | Novel promiscuous T helper cell epitopes |
| US6969609B1 (en) * | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| PL202399B1 (pl) | 1998-10-05 | 2009-06-30 | Pharmexa As | Zastosowanie adiuwanta i pierwszego analogu polipeptydowego antygenu związanego z komórką lub co najmniej jednego fragmentu kwasu nukleinowego kodującego epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką lub niepatogennego mikroorganizmu lub wirusa, który niesie fragment kwasu nukleinowego, który koduje i wyraża co najmniej jeden epitop CTL pochodzący z antygenu polipeptydowego związanego z komórką, sposób selekcji immunogennego analogu antygenu polipeptydowego związanego z komórką, sposób wytwarzania komórki wytwarzającej analog an |
| UA76731C2 (uk) | 2000-11-23 | 2006-09-15 | Баваріан Нордік А/С | Штам mva-bn модифікованого вірусу коров'ячої віспи ankara, фармацевтична композиція, вакцина, застосування mva-bn для приготування лікарського препарату та для приготування вакцини, спосіб введення гомологічної і/або гетерологічної послідовності нуклеїнової кислоти в клітини-мішені in vitro, спосіб одержання пептиду або білка, спосіб одержання mva-bn, клітина, набір для основної/бустерної імунізації |
| US7247615B2 (en) | 2001-11-30 | 2007-07-24 | United States Of America, Represented By The Secretary, Department Of Health And Human Services | Peptide agonists of prostate-specific antigen and uses therefor |
| CN1602316A (zh) | 2001-12-04 | 2005-03-30 | 巴法里安诺迪克有限公司 | 黄病毒ns1亚单位疫苗 |
| HUE037866T2 (hu) | 2006-06-20 | 2018-09-28 | Transgene Sa | Eljárás poxvírusok és poxvírus-készítmények elõállítására |
| DK2367944T3 (en) | 2008-11-27 | 2019-04-15 | Bavarian Nordic As | PROMOTERS FOR RECOMBINANT VIRAL EXPRESSION |
| US8394385B2 (en) | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| CA2860599C (en) | 2012-01-03 | 2021-07-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Native and agonist ctl epitopes of the muc1 tumor antigen |
| EP2864487B1 (en) | 2012-06-22 | 2018-12-05 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| WO2014037124A1 (en) | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| AU2013331328B2 (en) | 2012-10-19 | 2018-05-31 | Bavarian Nordic A/S | Methods and compositions for the treatment of cancer |
| UA118340C2 (uk) | 2012-10-28 | 2019-01-10 | Баваріан Нордік А/С | Промотор pr13.5 для стійких t-клітинних та гуморальних імунних реакцій |
| NZ725459A (en) * | 2014-05-13 | 2023-04-28 | Bavarian Nordic As | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
| KR20150135148A (ko) | 2014-05-23 | 2015-12-02 | 주식회사 제넥신 | Pd-l1 융합 단백질 및 이의 용도 |
| CN107949397A (zh) | 2015-02-13 | 2018-04-20 | 特兰斯吉恩股份有限公司 | 免疫治疗疫苗和抗体组合治疗 |
| RU2753884C2 (ru) | 2015-07-31 | 2021-08-24 | Бавариан Нордик А/С | Промоторы для усиления экспрессии в поксвирусах |
| SG11201807022XA (en) | 2016-02-25 | 2018-09-27 | Memorial Sloan Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| EP3589312A1 (en) * | 2017-03-03 | 2020-01-08 | New York University | Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins |
-
2019
- 2019-11-20 CA CA3119503A patent/CA3119503A1/en active Pending
- 2019-11-20 AU AU2019385665A patent/AU2019385665A1/en active Pending
- 2019-11-20 MX MX2021005560A patent/MX2021005560A/es unknown
- 2019-11-20 KR KR1020217014706A patent/KR20210094535A/ko active Pending
- 2019-11-20 EP EP19802224.6A patent/EP3883599A1/en active Pending
- 2019-11-20 SG SG11202104918PA patent/SG11202104918PA/en unknown
- 2019-11-20 WO PCT/EP2019/081942 patent/WO2020104531A1/en not_active Ceased
- 2019-11-20 JP JP2021527213A patent/JP7625518B2/ja active Active
- 2019-11-20 BR BR112021009856A patent/BR112021009856A8/pt unknown
- 2019-11-20 CN CN201980076127.2A patent/CN113056284A/zh active Pending
- 2019-11-20 US US17/295,384 patent/US12390515B2/en active Active
-
2021
- 2021-05-13 IL IL283187A patent/IL283187A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tsuji et al. | Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity | |
| Yu et al. | Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma | |
| US12390515B2 (en) | Therapy for treating cancer with an intratumoral or intravenous administration of a recombinant MVA encoding 4-1BBL (CD137L) and/or CD40L | |
| JPWO2020104531A5 (enExample) | ||
| US10072094B2 (en) | Compositions and methods for tumor transduction | |
| Lee et al. | Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects | |
| JP2017515841A5 (enExample) | ||
| EP3585426A1 (en) | Compositions and methods for tumor transduction | |
| Bronte et al. | Effective genetic vaccination with a widely shared endogenous retroviral tumor antigen requires CD40 stimulation during tumor rejection phase | |
| CN114867491A (zh) | 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒 | |
| Estevez-Ordonez et al. | Immunotherapy for pediatric brain and spine tumors: current state and future directions | |
| Chekaoui et al. | Cancer vaccines: an update on recent achievements and prospects for cancer therapy | |
| Berraondo et al. | Immunogenicity and efficacy of personalized adjuvant mRNA cancer vaccines | |
| Kamel et al. | Advancement insights in cancer vaccines: mechanisms, types, and clinical applications | |
| JPWO2021099586A5 (enExample) | ||
| RU2021117499A (ru) | Терапия для лечения рака с помощью внутриопухолевого и/или внутривенного введения рекомбинантного mva, кодирующего 4-1bbl (cd137l) и/или cd40l | |
| Taha et al. | Checkpoint inhibitors in gynecological malignancies: are we there yet? | |
| CN118574934A (zh) | 促融合弹状病毒糖蛋白及其用途 | |
| Giotta Lucifero et al. | Emerging immune-based technologies for high-grade gliomas | |
| EP4452305A1 (en) | Recombinant mva viruses for intraperitoneal administration for treating cancer | |
| Azad et al. | Glioblastoma antigen discovery—foundations for immunotherapy | |
| WO2007058235A1 (ja) | 融合蛋白質およびその薬学的用途 | |
| US20250051797A1 (en) | Engineered viral particles and uses of the same | |
| Zhao et al. | 5T4 oncotrophoblast glycoprotein: janus molecule in life and a novel potential target against tumors | |
| RU2830601C2 (ru) | Терапия для лечения рака с помощью внутриопухолевого и/или внутривенного введения рекомбинантного mva, кодирующего 4-1bbl (cd137l) и/или cd40l |